First Horizon Advisors, Inc. Sage Therapeutics, Inc. Transaction History
First Horizon Advisors, Inc.
- $3.81 Billion
- Q2 2025
A detailed history of First Horizon Advisors, Inc. transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, First Horizon Advisors, Inc. holds 1 shares of SAGE stock, worth $8. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1
Previous 1
-0.0%
Holding current value
$8
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding SAGE
# of Institutions
141Shares Held
38.6MCall Options Held
790KPut Options Held
440K-
Madison Avenue Partners, LP New York, NY6.08MShares$52.7 Million5.93% of portfolio
-
Black Rock Inc. New York, NY5.22MShares$45.3 Million0.0% of portfolio
-
Hudson Bay Capital Management LP Greenwich, CT1.95MShares$16.9 Million0.07% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY1.92MShares$16.6 Million0.01% of portfolio
-
Balyasny Asset Management LLC Chicago, IL1.52MShares$13.2 Million0.02% of portfolio
About Sage Therapeutics, Inc.
- Ticker SAGE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,422,300
- Market Cap $516M
- Description
- Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...